JP2020508648A - 蝸牛および前庭細胞に核酸を送達するための物質および方法 - Google Patents

蝸牛および前庭細胞に核酸を送達するための物質および方法 Download PDF

Info

Publication number
JP2020508648A
JP2020508648A JP2019542464A JP2019542464A JP2020508648A JP 2020508648 A JP2020508648 A JP 2020508648A JP 2019542464 A JP2019542464 A JP 2019542464A JP 2019542464 A JP2019542464 A JP 2019542464A JP 2020508648 A JP2020508648 A JP 2020508648A
Authority
JP
Japan
Prior art keywords
harmonin
mice
promoter
anc80
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019542464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508648A5 (https=
Inventor
ジェフリー ホルト
ジェフリー ホルト
グウェナエル ゲレオク
グウェナエル ゲレオク
友香子 浅井
友香子 浅井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2020508648A publication Critical patent/JP2020508648A/ja
Publication of JP2020508648A5 publication Critical patent/JP2020508648A5/ja
Priority to JP2023000088A priority Critical patent/JP7601916B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019542464A 2017-02-06 2018-02-06 蝸牛および前庭細胞に核酸を送達するための物質および方法 Withdrawn JP2020508648A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023000088A JP7601916B2 (ja) 2017-02-06 2023-01-04 蝸牛および前庭細胞に核酸を送達するための物質および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455197P 2017-02-06 2017-02-06
US62/455,197 2017-02-06
PCT/US2018/017104 WO2018145111A1 (en) 2017-02-06 2018-02-06 Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023000088A Division JP7601916B2 (ja) 2017-02-06 2023-01-04 蝸牛および前庭細胞に核酸を送達するための物質および方法

Publications (2)

Publication Number Publication Date
JP2020508648A true JP2020508648A (ja) 2020-03-26
JP2020508648A5 JP2020508648A5 (https=) 2021-03-18

Family

ID=63040112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019542464A Withdrawn JP2020508648A (ja) 2017-02-06 2018-02-06 蝸牛および前庭細胞に核酸を送達するための物質および方法
JP2023000088A Active JP7601916B2 (ja) 2017-02-06 2023-01-04 蝸牛および前庭細胞に核酸を送達するための物質および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023000088A Active JP7601916B2 (ja) 2017-02-06 2023-01-04 蝸牛および前庭細胞に核酸を送達するための物質および方法

Country Status (7)

Country Link
US (2) US11730827B2 (https=)
EP (1) EP3576696A4 (https=)
JP (2) JP2020508648A (https=)
CN (1) CN111698975A (https=)
AU (2) AU2018215785B2 (https=)
CA (1) CA3052704A1 (https=)
WO (1) WO2018145111A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220124603A (ko) * 2021-03-03 2022-09-14 연세대학교 산학협력단 Kcnq4 유전자 교정용 가이드 rna 및 이를 포함하는 난청 치료용 조성물

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
DE102018103924A1 (de) * 2018-02-21 2019-08-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Gentherapeutische Behandlung von Schwerhörigkeit
EP3762040A4 (en) 2018-03-05 2022-01-05 Children's Medical Center Corporation COMPOSITIONS AND METHODS OF ADMINISTRATION OF NUCLEIC ACIDS TO COCHLEAR AND VESTIBULAR CELLS
CN112703016B (zh) 2018-04-27 2024-11-22 分贝治疗公司 肌球蛋白15启动子及其用途
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
EP3856227A4 (en) 2018-09-27 2022-07-06 Akouos, Inc. METHODS OF TREATMENT OF AUDITORY NEUROPATHY SPECTRUM DISEASE
WO2020077295A1 (en) 2018-10-11 2020-04-16 Decibel Therapeutics, Inc. Aav1 vectors and uses thereof for treatment of otic indications
EP3897679A1 (en) * 2018-12-21 2021-10-27 Wade Wei-De Chien Adeno-associated viruses and their uses for inner ear therapy
CA3129422A1 (en) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
EP3921032A4 (en) * 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
EP3959324B1 (en) * 2019-04-26 2025-09-17 President and Fellows of Harvard College Aav vectors encoding mini-pcdh15 and uses thereof
JP2022530457A (ja) 2019-04-26 2022-06-29 サンガモ セラピューティクス， インコーポレイテッド 遺伝子操作ａａｖ
EP4007814A1 (en) * 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
KR20220130093A (ko) 2019-10-30 2022-09-26 데시벨 테라퓨틱스, 인크. 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 조성물 및 방법
EP4055175A4 (en) * 2019-11-04 2023-11-29 Decibel Therapeutics, Inc. Cochlear inner hair cell promoters and uses thereof
TWI902721B (zh) * 2019-11-04 2025-11-01 美商迪賽博治療公司 前庭支持細胞啟動子及其用途
WO2021150850A1 (en) * 2020-01-24 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Svcs. Adeno-associated viruses and their uses for inner ear therapy
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
EP4262882A1 (en) * 2020-12-18 2023-10-25 Institut Pasteur Gene therapy for treating usher syndrome
CN114762733B (zh) * 2021-01-15 2025-03-18 中国科学院脑科学与智能技术卓越创新中心 耳蜗外毛细胞特异性顺式调节元件及其应用
WO2023147383A1 (en) 2022-01-25 2023-08-03 Bridgebio Services Inc. Gene therapy for genetic hearing loss
CN121263526A (zh) * 2023-05-23 2026-01-02 苏州星奥拓维生物技术有限公司 耳蜗毛细胞特异性启动子及其用途
CN119061007A (zh) * 2023-06-02 2024-12-03 苏州星奥拓维生物技术有限公司 耳蜗支持细胞基因治疗和再生的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287127A1 (en) * 2003-11-13 2005-12-29 Huawei Li Use of stem cells to generate inner ear cells
US20130095071A1 (en) * 2009-12-21 2013-04-18 Audigen Inc. Method of treating or preventing hearing loss
JP2016536011A (ja) * 2013-10-11 2016-11-24 マサチューセッツ アイ アンド イヤー インファーマリー 祖先ウイルス配列を予測する方法およびその使用
JP2018536420A (ja) * 2015-12-11 2018-12-13 マサチューセッツ アイ アンド イヤー インファーマリー 蝸牛および前庭細胞に核酸を送達するための材料および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100990160B1 (ko) * 2010-03-15 2010-10-29 도태환 기전력 안정화 영구자석 발전기
JP7103750B2 (ja) * 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
WO2017136764A1 (en) * 2016-02-05 2017-08-10 The General Hospital Corporation Hybrid system for efficient gene delivery to cells of the inner ear
WO2018017834A1 (en) * 2016-07-21 2018-01-25 The Regents Of The University Of California Methods for inducing stereocilia on hair cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287127A1 (en) * 2003-11-13 2005-12-29 Huawei Li Use of stem cells to generate inner ear cells
US20130095071A1 (en) * 2009-12-21 2013-04-18 Audigen Inc. Method of treating or preventing hearing loss
JP2016536011A (ja) * 2013-10-11 2016-11-24 マサチューセッツ アイ アンド イヤー インファーマリー 祖先ウイルス配列を予測する方法およびその使用
JP2018536420A (ja) * 2015-12-11 2018-12-13 マサチューセッツ アイ アンド イヤー インファーマリー 蝸牛および前庭細胞に核酸を送達するための材料および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
53RD WORKSHOP INNER EAR BIOLOGY, 2016, SEPTEMBER 17-21, ABSTRACT BOOK, P.35, S7, JPN6021043823, ISSN: 0005003942 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220124603A (ko) * 2021-03-03 2022-09-14 연세대학교 산학협력단 Kcnq4 유전자 교정용 가이드 rna 및 이를 포함하는 난청 치료용 조성물
KR102751019B1 (ko) 2021-03-03 2025-01-09 연세대학교 산학협력단 Kcnq4 유전자 교정용 가이드 rna 및 이를 포함하는 난청 치료용 조성물

Also Published As

Publication number Publication date
EP3576696A4 (en) 2020-09-16
JP2023036921A (ja) 2023-03-14
AU2018215785A9 (en) 2019-09-26
WO2018145111A9 (en) 2019-08-29
CA3052704A1 (en) 2018-08-09
AU2023214288A1 (en) 2023-11-30
EP3576696A1 (en) 2019-12-11
AU2018215785A1 (en) 2019-08-22
WO2018145111A1 (en) 2018-08-09
US11730827B2 (en) 2023-08-22
AU2018215785B2 (en) 2023-08-31
CN111698975A (zh) 2020-09-22
US20190351072A1 (en) 2019-11-21
JP7601916B2 (ja) 2024-12-17
US20230330268A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US20230330268A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
JP7745594B2 (ja) 蝸牛および前庭細胞に核酸を送達するための材料および方法
JP7430652B2 (ja) 蝸牛および前庭細胞に核酸を送達するための組成物および方法
JP2023515072A (ja) ヒト対象において非加齢関連聴力障害を処置するための組成物および方法
HK40095383A (zh) 用於将核酸递送至耳蜗和前庭细胞的材料和方法
HK40074395A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK1262434B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK40003977B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK40003977A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
Smyrnakou-Biedenbänder Synaptic Transmission in the Inner Ear Between Basic Research and Gene Therapy
WO2026043797A1 (en) Methods and compositions for prevention and treatment of hearing loss

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230124

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230125

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230303

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230308

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240326

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241022